OncoMatch/Clinical Trials/NCT06902376
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Is NCT06902376 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Cemiplimab and XL092 for anaplastic thyroid cancer.
Treatment: Cemiplimab · XL092 — This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: BRAF wild-type
Must have BRAF V600E mutation-negative tumor, as determined by BRAF V600E immunohistochemistry on tumor tissue or genetic/molecular testing of the tumor.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: immune modulating agent
Exception: patients with documented disease progression on these agents will not be eligible
Patients who have had prior exposure to any immune modulating agents or any type of small molecule kinase inhibitor (including investigational agents) and have documented disease progression on these agents will not be eligible.
Cannot have received: small molecule kinase inhibitor
Exception: patients with documented disease progression on these agents will not be eligible
Patients who have had prior exposure to any immune modulating agents or any type of small molecule kinase inhibitor (including investigational agents) and have documented disease progression on these agents will not be eligible.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber/Harvard Cancer Center · Boston, Massachusetts
- University of North Carolina at Chapel Hill · Chapel Hill, North Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06902376 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune modulating agent, small molecule kinase inhibitor disqualifies patients from enrollment.
Does this trial require BRAF?
Yes, BRAF wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify